DK0866704T3 - Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose - Google Patents

Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose

Info

Publication number
DK0866704T3
DK0866704T3 DK96934975T DK96934975T DK0866704T3 DK 0866704 T3 DK0866704 T3 DK 0866704T3 DK 96934975 T DK96934975 T DK 96934975T DK 96934975 T DK96934975 T DK 96934975T DK 0866704 T3 DK0866704 T3 DK 0866704T3
Authority
DK
Denmark
Prior art keywords
ylethyl
naphth
tetrahydropyridine
trifluoromethylphenyl
treatment
Prior art date
Application number
DK96934975T
Other languages
Danish (da)
English (en)
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0866704T3 publication Critical patent/DK0866704T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DK96934975T 1995-10-26 1996-10-25 Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose DK0866704T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (1)

Publication Number Publication Date
DK0866704T3 true DK0866704T3 (da) 2001-07-16

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96934975T DK0866704T3 (da) 1995-10-26 1996-10-25 Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose

Country Status (28)

Country Link
US (1) US6043251A (zh)
EP (1) EP0866704B1 (zh)
JP (1) JP3468526B2 (zh)
KR (1) KR100472793B1 (zh)
CN (1) CN1104241C (zh)
AT (1) ATE200423T1 (zh)
AU (1) AU719342B2 (zh)
BR (1) BR9611124A (zh)
CA (1) CA2235747C (zh)
CY (1) CY2279B1 (zh)
CZ (1) CZ293360B6 (zh)
DE (1) DE69612510T2 (zh)
DK (1) DK0866704T3 (zh)
EE (1) EE04177B1 (zh)
ES (1) ES2159362T3 (zh)
GR (1) GR3036027T3 (zh)
HK (1) HK1016904A1 (zh)
HU (1) HU222039B1 (zh)
IL (1) IL124091A (zh)
IS (1) IS1961B (zh)
NO (1) NO316256B1 (zh)
NZ (1) NZ320355A (zh)
PT (1) PT866704E (zh)
SI (1) SI0866704T1 (zh)
SK (1) SK284099B6 (zh)
TR (1) TR199800717T2 (zh)
UA (1) UA57004C2 (zh)
WO (1) WO1997015304A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
PL374310A1 (en) * 2001-12-11 2005-10-03 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
ES2334061T3 (es) * 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PT3019167T (pt) 2013-07-12 2021-03-04 Knopp Biosciences Llc Tratamento de níveis elevados de eosinófilos e/ou basófilos
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
NO316256B1 (no) 2004-01-05
NO981856L (no) 1998-06-11
HK1016904A1 (en) 1999-11-12
HUP9802945A3 (en) 1999-05-28
CN1104241C (zh) 2003-04-02
CZ129698A3 (cs) 1998-07-15
CY2279B1 (en) 2003-07-04
BR9611124A (pt) 1999-05-11
MX9803271A (es) 1998-09-30
GR3036027T3 (en) 2001-09-28
HU222039B1 (hu) 2003-03-28
KR19990067057A (ko) 1999-08-16
EP0866704B1 (fr) 2001-04-11
AU719342B2 (en) 2000-05-04
CN1202826A (zh) 1998-12-23
TR199800717T2 (xx) 1998-09-21
IS1961B (is) 2004-11-15
IL124091A (en) 2003-10-31
PT866704E (pt) 2001-07-31
DE69612510T2 (de) 2001-11-22
WO1997015304A1 (fr) 1997-05-01
IS4722A (is) 1998-04-21
CA2235747C (en) 2006-01-03
JPH11515012A (ja) 1999-12-21
ES2159362T3 (es) 2001-10-01
JP3468526B2 (ja) 2003-11-17
KR100472793B1 (ko) 2005-06-16
SK284099B6 (sk) 2004-09-08
CZ293360B6 (cs) 2004-04-14
EP0866704A1 (fr) 1998-09-30
SI0866704T1 (en) 2001-08-31
DE69612510D1 (de) 2001-05-17
SK52698A3 (en) 1998-09-09
HUP9802945A2 (hu) 1999-04-28
CA2235747A1 (en) 1997-05-01
AU7308496A (en) 1997-05-15
ATE200423T1 (de) 2001-04-15
UA57004C2 (uk) 2003-06-16
US6043251A (en) 2000-03-28
NZ320355A (en) 2000-03-27
EE04177B1 (et) 2003-12-15
EE9800132A (et) 1998-10-15
NO981856D0 (no) 1998-04-24

Similar Documents

Publication Publication Date Title
DK0866704T3 (da) Anvendelse af 1-(2-naphth-2-ylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af amyotrofisk lateralsklerose
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes)
FR2765107B1 (fr) Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
PT706395E (pt) Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo
SE9501881D0 (sv) New pharmacological use of AII-receptor antagonists
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
DK0825859T3 (da) Anvendelse af forskolin eller ekstrakter indeholdende dette til fremstilling af et lægemiddel til behandling af alkoholafhængighed
DE19681129D2 (de) Verwendung des alpha,alpha-Diphenylessigsäure-4-(N-Methyl-Piperidyl)esters als Spasmoanalgetikum